
LOS ANGELES, May 29, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Rocket Pharmaceuticals, Inc. (“Rocket” or “the Company”) (NASDAQ: RCKT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Rocket investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On May 27, 2025, Rocket Pharmaceuticals issued a press release providing an update regarding RP-A501, its investigational gene therapy for Danon disease. The company reported that a participant in the Phase 2 pivotal trial experienced an unexpected Serious Adverse Event (SAE), which involved clinical complications consistent with capillary leak syndrome. Following the incident, Rocket voluntarily suspended further dosing in the study. Subsequently, on May 23, 2025, the U.S. Food and Drug Administration (FDA) imposed a clinical hold on the trial to allow for additional assessment. The press release also disclosed that the patient later died as a result of an acute systemic infection.
Following this announcement, Rocket’s stock price declined by $3.94 per share, or approximately 62.84%, closing at $2.33 per share on May 27, 2025.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bars
[email protected]
310-692-8883
www.portnoylaw.com
Attorney Advertising
Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow